查看文章

Results

Five RCTs (n= 1067) and 6 cohorts (n= 881) were included. Three and 1 RCTs had some concerns and high RoB, respectively; and there was serious RoB in all cohorts. Convalescent plasma did not reduce all-cause mortality in RCTs of severe (RR= 0.60, 95% CI: 0.33–1.10) or moderate (RR= 0.60, 95% CI: 0.09–3.86) COVID-19 vs. standard of care (SOC); CP reduced all-cause mortality vs. SOC in cohorts (RR= 0.66, 95% CI: 0.49–0.91). Convalescent plasma did not reduce invasive ventilation vs. SOC in moderate disease (RR= 0.85, 95% CI: 0.47–1.55). In comparison to placebo+ SOC, CP did not affect all-cause mortality (RR= 0.75, 95% CI: 0.48–1.16) or clinical improvement (HR= 1.07, 95% CI: 0.82–1.40) in severe patients. Adverse and serious adverse events were scarce, similar between CP and controls. Quality of evidence was low or very low for most outcomes.

Conclusions

In comparison to SOC or …